ABL1 and leukemia: Since asciminib is distinctive in that it functions as an allosteric inhibitor, attaching to the BCR-ABL1 protein’s myristoyl pocket and immobilizing it in an inactive conformation, it is widely administered for the treatment of (Ph+)leukemia [6].